Essential atlas of heart diseases

著者

書誌事項

Essential atlas of heart diseases

editor-in-chief, Eugene Braunwald ; contributing editors, Kenneth L. Baughman ... [et al.]

McGraw-Hill, c2001

2nd ed

大学図書館所蔵 件 / 全5件

この図書・雑誌をさがす

注記

Includes bibliographical references and index

"Developed by Current Medicine, Inc., Philadelphia"

内容説明・目次

内容説明

A full-color atlas designed to provide all health care professionals with a detailed pictorial presentation of cardiovascular diseases and their treatment. Updated throughout, the Second Edition highlights important points in summary boxes, and features information on new drugs and clinical trials.

目次

  • Specific Changes as Described by Current Science
  • Chapter 1: New figure on the Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial. Added two new figures, Lipid Concentrations According to Year of Study and Treatment Group
  • Kaplan-Meier Estimates of the Incidence of Death from Coronary Heart Disease and Nonfatal Myocardial Infarction in the Gemfibrozil and Placebo Groups. Chapter 2: Figure 2-15 replaced with new figure showing the systematic overview of ACE inhibitor trials post-myocardial infarction. Figure 2-18 replaced with figure listing the antithrombotic agents in acute coronary systems. Figure 2-19 replaced with figure showing the systematic overview of aspirin vs heparin clinical trials. Figure 2-28 replaced by new table on characteristics of thrombolytic agents. New figure added showing results of the Gusto III trial and Assent II trial. Figure 2-43 replaced with figure showing systematic overview of various glycoprotein Iib/IIIa inhibitors vs placebo trials in acute coronary syndromes. New figure showing outcomes of before and after percutaneous intervention in patients treated with glycoprotein Iib/IIIa inhibitors. New figure comparing direct PTCA and thrombolysis. Figure 2-51 replaced by the survivial curves from the Shock Trial. Chapter 4: New sections "Molecular and Cellular Mechanisms of Myocardial Remodeling," "Matrix remodeling," and "Inflammatory Cytokines" Chapter 7: Revise figure 7-51 to include angiotensin-receptor blockers. Added info on the Syst-Eur study, losartan, eprosartan, and dual metalloproteinase and vasopeptidase inhibitors. Chapter 8: New tables "Indications for Surgery for Severe for AS" and "Valve Selection for an Individual Patient" Chapter 9: See author's letter in your mailbox. Dr. Freedom determined that this chapter did not need updating
  • Braunwald approved. Chapter 10: New figures on Manifestations of Upper-airway Closure, cardiac myxoma.

「Nielsen BookData」 より

詳細情報

ページトップへ